Lubiprostone Combination Therapy for Residual-Function CFTR
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cystic fibrosis, particularly in patients with CFTR residual function mutations, do not provide significant improvement in lung function, and existing CFTR modulators like lumacaftor and ivacaftor are ineffective for compound heterozygous patients.
Innovation Solution
Administering lubiprostone, a CFTR activator, in combination with CFTR potentiators and correctors, to enhance chloride transporting ability in CFTR channels with residual function mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CFTR modulators like lumacaftor and ivacaftor are used, then treatment efficacy is improved for certain CFTR mutations, but they are ineffective for compound heterozygous patients and those with residual function mutations
Solution Approach 1:
The patent employs a multi-component CFTR modulator regimen that addresses multiple mutation types simultaneously. The combination includes correctors (e.g., lumacaftor) for folding defects, potentiators (e.g., ivacaftor) for gating defects, and activators (e.g., forskolin, rolipram) that can enhance CFTR function across various mutation backgrounds, creating a universal treatment approach for compound heterozygous and residual function mutations
Solution Approach 2:
The invention uses composite pharmaceutical formulations combining multiple CFTR modulators with different mechanisms of action. This composite approach integrates correctors, potentiators, and activators to achieve synergistic effects that broaden coverage across diverse CFTR mutation spectra, particularly benefiting compound heterozygous patients who require multiple mechanisms to achieve adequate CFTR function
2Reliability
If CFTR modulators are administered, then chloride transport is enhanced in some patients, but lung function improvement is not significant in patients with residual function mutations
Solution Approach 1:
The patent employs preliminary pharmacological chaperone therapy using correctors to stabilize CFTR protein folding and promote proper trafficking to the cell surface before administering potentiators and activators. This sequential approach ensures that sufficient functional CFTR channels are available at the apical membrane to respond to subsequent potentiation and activation, thereby improving lung function in patients with residual function mutations
Solution Approach 2:
The invention optimizes multiple parameters including dosing regimens, combination ratios of different modulators, and timing of administration to maximize lung function improvement. By adjusting these parameters in combination therapy regimens, the patent achieves synergistic effects that translate chloride transport enhancement into clinically meaningful lung function improvements
3Adaptability or versatility
If multiple CFTR modulators are combined, then coverage of different mutation types is improved, but treatment complexity increases
Solution Approach 1:
The patent merges multiple CFTR modulators into integrated treatment regimens where correctors, potentiators, and activators work synergistically. By combining these agents with complementary mechanisms of action, the invention achieves broad mutation type coverage while managing complexity through rational drug selection and coordinated administration protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances chloride transport in both non-CFTR and corrected/potentiated F508del CFTR, improving lung function and reducing disease severity in patients with residual function mutations.
Implementation Method 1
lubiprostone, a CFTR activator, to enhance chloride transporting ability in CFTR channels with residual function mutations
Data Source
Figure 1A
Figure 1B~1C
Figure 2A
AI summary
Methods of treating cystic fibrosis transmembrane conductance regulator (CFTR)-mediated disease, such as cystic fibrosis, in patients with residual function mutations.